drugset

drugset / Trial / NCT00297687

Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

NCT00297687 ↗

Phase 1 Completed 108 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupDouble-blindPrevention

Summary

To determine the safety \& immunogenicity of a potential vaccine against meningococcal B disease

Timeline

Start: 2006-03
Primary completion: —
Completion: 2007-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MnB rLP2086	Vaccine	—	—

Indications